全文获取类型
收费全文 | 400篇 |
免费 | 17篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 37篇 |
妇产科学 | 2篇 |
基础医学 | 49篇 |
口腔科学 | 9篇 |
临床医学 | 59篇 |
内科学 | 75篇 |
皮肤病学 | 3篇 |
神经病学 | 10篇 |
特种医学 | 79篇 |
外科学 | 23篇 |
综合类 | 28篇 |
预防医学 | 20篇 |
眼科学 | 2篇 |
药学 | 16篇 |
中国医学 | 1篇 |
肿瘤学 | 9篇 |
出版年
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 1篇 |
2016年 | 2篇 |
2015年 | 5篇 |
2014年 | 7篇 |
2013年 | 9篇 |
2012年 | 5篇 |
2011年 | 3篇 |
2010年 | 12篇 |
2009年 | 7篇 |
2008年 | 8篇 |
2007年 | 12篇 |
2006年 | 13篇 |
2005年 | 13篇 |
2004年 | 6篇 |
2003年 | 14篇 |
2002年 | 14篇 |
2001年 | 10篇 |
2000年 | 22篇 |
1999年 | 14篇 |
1998年 | 28篇 |
1997年 | 28篇 |
1996年 | 18篇 |
1995年 | 13篇 |
1994年 | 19篇 |
1993年 | 9篇 |
1992年 | 13篇 |
1991年 | 15篇 |
1990年 | 11篇 |
1989年 | 12篇 |
1988年 | 11篇 |
1987年 | 5篇 |
1986年 | 11篇 |
1985年 | 6篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 8篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 7篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 3篇 |
1973年 | 1篇 |
1971年 | 1篇 |
1969年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有424条查询结果,搜索用时 15 毫秒
1.
2.
S W Pyle B Morein J W Bess L Akerblom P L Nara S M Nigida N W Lerche W G Robey P J Fischinger L O Arthur 《Vaccine》1989,7(5):465-473
In mice, immunostimulatory complexes (ISCOMs) prepared from HIV-1 B external envelope glycoprotein (gp120) induced 10-fold higher antibody titres than gp120 emulsified in depot adjuvant, as measured by enzyme-linked immunosorbent assay (ELISA). Rhesus monkeys immunized with gp120 ISCOMs produced precipitating and virus neutralizing antibody titres equivalent to those seen in HIV-infected chimpanzees and humans. After multiple immunizations with HIV-1 B gp120 ISCOMs, a rhesus monkey developed a neutralizing response to the HIV-1 isolates RF and MN, but not to the CC isolate. Antisera from ISCOM-immunized rhesus monkeys recognized gp120 on the membranes of HIV-1 B-infected H9 cells, indicating the preservation of epitope structure in the ISCOMs matrix. 相似文献
3.
Estimation of genetic risk for type 1 diabetes 总被引:8,自引:0,他引:8
Ilonen J Sjöroos M Knip M Veijola R Simell O Akerblom HK Paschou P Bozas E Havarani B Malamitsi-Puchner A Thymelli J Vazeou A Bartsocas CS 《American journal of medical genetics》2002,115(1):30-36
The most important gene loci defining risk of type 1 diabetes mellitus (T1DM) are located within the HLA gene region. HLA-DQ molecules are of primary importance but HLA-DR gene products modify the risk conferred by HLA-DQ. The risk associated with an HLA genotype is defined by the particular combination of susceptible and protective alleles. The highest risk is associated with a combination of two different risk haplotypes (7% risk to develop T1DM in Finland) whereas protective genotypes covering 69% of population have a risk of less than 0.2%). The complicated analysis of HLA genotypes is simplified by strong linkage disequilibrium between HLA-DRB1, -DQA1 and -DQB1 loci. In many cases one can deduce the alleles of other loci based on determination of the alleles in one locus. Differences between various populations in the frequency of marker alleles and in the linkages between them has to be taken into account. We have developed PCR based typing methods that utilize blood spot samples, microtiter plate format and lanthanide labeled oligonucleotide probes to define HLA-DQ and -DR alleles relevant for T1DM risk. Typing is run stepwise so that after initial HLA-DQB1 typing only those samples will be further analyzed in which -DQA1 or -DRB1 typing is informative and expected to contribute to the risk estimation. This method has been used to screen more than 50,000 newborn infants in Finland over a time period of 6 years, and it has been able to identify most children who have developed T1D during the follow-up period. The efficiency of the procedure has also been tested in Finnish and Greek populations. 相似文献
4.
S Ahlstedt B Bj?rkstén E Akerblom 《International archives of allergy and applied immunology》1983,71(3):228-232
Antibody responses of the IgE isotype were raised in mice with honey-bee venom (HBV) administered in alum or by daily injections without adjuvant. The sensitized mice were treated with single injections of HBV modified with monomethoxy-polyethylene glycol. By such treatment with modified but not with natural HBV, suppression of the IgE antibody responses was achieved. The IgG antibody responses, in contrast, were unchanged or enhanced. 相似文献
5.
6.
Heeney J Akerblom L Barnett S Bogers W Davis D Fuller D Koopman G Lehner T Mooij P Morein B de Giuli Morghen C Rosenwirth B Verschoor E Wagner R Wolf H 《Immunology letters》1999,66(1-3):189-195
The specific immune mechanisms necessary and/or sufficient to elicit HIV-vaccine protection remain undefined. Utilising the SHIV rhesus macaque model the immunogenicity as well as the efficacy of ten different HIV-1 vaccine candidates was evaluated. Comparison of the immune responses induced, with the ability of the vaccine to protect from SHIV infection provided a means to determine which type of immune responses were necessary for protection. Vaccine candidates included VLPs, DNA, subunit protein with novel adjuvant formulations, ISCOMs and pox-virus vectors. Protection from SHIV infection was achieved in approximately half of the animals which received a primary intravenous cell-free challenge. The presence of CTL in the absence of other effector responses did not correlate with protection from this route and type of challenge. Virus neutralising antibodies (Nab) appeared to be necessary but alone were insufficient for protection. If Ag-specific IFN-gamma and/or IL-4 as well as lymphoproliferative (LP) responses were found with the lack of a detectable IL-2 response, then protection was not observed. Immunity correlated with the magnitude of Nab responses, beta-chemokines and as well as balanced, qualitative T-helper responses. 相似文献
7.
Vaccine protection against HIV-2 infection in cynomolgus monkeys 总被引:9,自引:0,他引:9
P Putkonen R Thorstensson L Walther J Albert L Akerblom O Granquist G Wadell E Norrby G Biberfeld 《AIDS research and human retroviruses》1991,7(3):271-277
The aim of this study was to determine if protection against an infectious human immunodeficiency virus type 2 (HIV-2) challenge could be obtained in cynomolgus macaques by active immunization using whole killed virus vaccine. Four monkeys were immunized with killed HIV-2SBL-6669, two of them with five intramuscular (im) injections of viral preparation containing 100 or 300 micrograms protein emulsified in incomplete Freund's adjuvant (IFA) and the two remaining received four im injections of 25-50 micrograms viral protein in iscoms. Each of the four vaccinated cynomolgus monkeys, along with four unvaccinated controls, were challenged intravenously two weeks after the last booster with approximately 100 animal infectious doses (ID50) of live HIV-2SBL-6669. All four immunized monkeys developed antibodies to HIV-2 envelope and core proteins before challenge exposure to HIV-2, but only the two animals vaccinated with virus in IFA developed detectable neutralizing antibodies. The two monkeys immunized with killed virus in IFA have shown no evidence of infection nine months after challenge with live virus. When blood and lymph node cells from these animals were transfused into naive cynomolgus monkeys, the recipients remained free of infection. In contrast, virus was recovered repeatedly in all nonimmunized animals and in the two animals immunized with iscom-associated viral antigens, which had a low content of envelope gp125 antigen. The demonstration of vaccine-induced protection against HIV-2 in a nonhuman primate raises hope for effective immunization against HIV infections in humans as well. 相似文献
8.
9.
10.
Baumgartner C; Morell A; Hirt A; Bucher U; Forster HK; Doran JE; Matter L; Brun del Re G; Wagner HP 《Blood》1988,71(5):1211-1217
Elimination of neoplastic B cell populations from autologous bone marrow grafts also removes normal B lymphocytes. This is potentially hazardous for the reconstitution of the immune system in patients undergoing high-dose chemotherapy and total body irradiation followed by autologous marrow rescue. Five pediatric patients with B cell non- Hodgkin's lymphoma in first remission undergoing such a regimen were studied. They received bone marrow pretreated with anti-Y 29/55 monoclonal antibody and complement. B and T lymphocyte subpopulations reached normal levels within 6 months after autologous bone marrow transplantation (ABMT), and serum immunoglobulin levels became normal within 4 to 9 months. Vaccination with diphtheria and tetanus toxoid, trivalent poliomyelitis vaccine of the Salk type, and pneumococcal capsular antigens (38 to 54 months after transplantation) gave rise to specific antibody production. ABO isoagglutinins could be demonstrated in all patients. The response pattern was similar to that of patients who received unmanipulated autologous bone marrow. It is concluded that ex vivo anti-Y 29/55 depletion of the marrow graft does not induce relevant disturbances of humoral immune functions. 相似文献